Oncologists in the UK and India will begin recruiting up to 10,000 patients early next year for a clinical trial on a drug that has been for sale for at least 115 years.
The team will be giving low-dose aspirin to people who have had initial treatment for four different types of cancer to see if the drug helps prevent the development of secondary tumours.
The Add-Aspirin study is being run jointly by the NHS National Institute for Health Research and Cancer Research UK and will target roughly equal numbers of patients that have breast, colorectal, gastro-intestinal and prostate cancers.
This article is only available to Research Professional News subscribers or Pivot-RP users.
If you are a Research Professional News subscriber you can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.